Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 15 of 1,261
  1. US 12410259

    CD47 targeted therapies for the treatment of infectious disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  2. US 12410398

    Methods of human retinal progenitor cell isolation and culture

    The Regents of the University of California · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  3. US 12410225

    Modulation of dendritic cell lineages

    Orionis Biosciences, Inc · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  4. US 12410170

    2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

    Arcus Biosciences, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  5. US 12410153

    Compounds, compositions and methods

    AVALO THERAPEUTICS, INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  6. US 12409213

    Live attenuated oral vaccine against shigellosis and typhoid fever

    Sanaria Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  7. US 12409227

    Cochleates made with soy phosphatidylserine

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  8. US 12409188

    Modulators of HSD17B13 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  9. US 12410232

    Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

    The Board of Regents of the University of Texas System · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  10. US 12409197

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  11. US 12409205

    Nanomolecules for the treatment of inflammatory bowel diseases

    Northwestern University · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  12. US 12410184

    Crystalline forms of a menin inhibitor

    Kura Oncology, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  13. US 12409225

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  14. US 12409224

    Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  15. US 12409206

    Use of cyclosporine analogues for treating fibrosis

    Hepion Pharmaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  16. US 12410137

    Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

    APOGEE PHARMACEUTICALS, INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  17. US 12410240

    Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  18. US 12410249

    Low dose antibody-based methods for treating hematologic malignancies

    Actinium Phamaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  19. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  20. US 12410132

    Antiplatelet drugs and uses thereof

    SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  21. US 12409228

    Hydrogel drug delivery systems for the treatment of pediatric growth plate injuries

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  22. US 12409220

    Conjugate polypeptides and vaccines for inducing immune responses

    The Regents of the University of California · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  23. WO 2025184490

    N-[4-FLUOR-5-[[(2S,4R)-4-[(6-MÉTHOXY-4-PYRIMIDNYL)OXY]-2-MÉTHYL-1-PYRROLIDINYL]MÉTHYL]-2-THIAZOLYL]ACÉTAMIDE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Sep 4, 2025 · Expires Aug 30, 2045

    granted
  24. US 12404313

    GDNF fusion polypeptides and methods of use thereof

    Keros Therapeutics, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.